IFNA2: The Prototypic Human Alpha Interferon

Overview

Journal Gene

Specialty Molecular Biology

Date 2015 May 19

PMID 25982860

Citations 29

Authors

Franciane Paul

Sandra Pellegrini

Gilles Uze

Affiliations

Soon will be listed here.

Abstract

The human interferon α2 (IFNα2) was the first highly active IFN subtype to be cloned in the early eighties. It was also the first IFN and the first cytokine to be produced and commercialized by the pharmaceutical industry. Ipso facto it became the favorite IFNα subtype for academic researchers. For this fortunate reason IFNα2 has been at the origin of most discoveries related to the mechanism of action of type I interferons.

Citing Articles

Evidence of innate training in bovine γδ T cells following subcutaneous BCG administration.

Samuel B, Diaz F, Maina T, Corbett R, Tuggle C, McGill J Front Immunol. 2024; 15:1423843.

PMID: 39100669 PMC: 11295143. DOI: 10.3389/fimmu.2024.1423843.

Targeted Mass Spectrometry Reveals Interferon-Dependent Eicosanoid and Fatty Acid Alterations in Chronic Myeloid Leukaemia.

Scott H, Draganov S, Yu Z, Kessler B, Pinto-Fernandez A Int J Mol Sci. 2023; 24(21).

PMID: 37958498 PMC: 10649737. DOI: 10.3390/ijms242115513.

Identification of novel clusters of co-expressing cytokines in a diagnostic cytokine multiplex test.

Polley D, Latham P, Choi M, Buhler K, Fritzler M, Fritzler M Front Immunol. 2023; 14:1223817.

PMID: 37600813 PMC: 10432683. DOI: 10.3389/fimmu.2023.1223817.

The Cell-Mediated Immune Response against (BoHV-1) Infection and Vaccination.

Righi C, Franzoni G, Feliziani F, Jones C, Petrini S Vaccines (Basel). 2023; 11(4).

PMID: 37112697 PMC: 10144493. DOI: 10.3390/vaccines11040785.

Azithromycin and Ceftriaxone Differentially Activate NLRP3 in LPS Primed Cancer Cells.

Tezcan G, Alsaadi M, Hamza S, Garanina E, Martynova E, Ziganshina G Int J Mol Sci. 2022; 23(16).

PMID: 36012769 PMC: 9409354. DOI: 10.3390/ijms23169484.

References

Tomasello E, Pollet E, Vu Manh T, Uze G, Dalod M . Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol. 2014; 5:526. PMC: 4214202. DOI: 10.3389/fimmu.2014.00526. View

Diamond M, Kinder M, Matsushita H, Mashayekhi M, Dunn G, Archambault J . Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011; 208(10):1989-2003. PMC: 3182061. DOI: 10.1084/jem.20101158. View

Pestka S, Krause C, Walter M . Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004; 202:8-32. DOI: 10.1111/j.0105-2896.2004.00204.x. View

Uze G, Tavernier J . High efficiency targeting of IFN-α activity: possible applications in fighting tumours and infections. Cytokine Growth Factor Rev. 2014; 26(2):179-82. DOI: 10.1016/j.cytogfr.2014.10.006. View

Wilmes S, Beutel O, Li Z, Francois-Newton V, Richter C, Janning D . Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling. J Cell Biol. 2015; 209(4):579-93. PMC: 4442803. DOI: 10.1083/jcb.201412049. View

Rizza P, Moretti F, Capone I, Belardelli F . Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 2014; 26(2):195-201. DOI: 10.1016/j.cytogfr.2014.10.002. View

Isaacs A, Lindenmann J . Pillars Article: Virus Interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 258-267. J Immunol. 2015; 195(5):1911-20. View

Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F . Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2010; 71(3):768-78. DOI: 10.1158/0008-5472.CAN-10-2788. View

Talpaz M, Kantarjian H, McCredie K, Keating M, Trujillo J, Gutterman J . Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987; 69(5):1280-8. View

10.

Qi Z, Nie P, Secombes C, Zou J . Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs. J Immunol. 2010; 184(9):5038-46. DOI: 10.4049/jimmunol.0903374. View

11.

Schoggins J, Rice C . Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2012; 1(6):519-25. PMC: 3274382. DOI: 10.1016/j.coviro.2011.10.008. View

12.

Lawn R, Adelman J, Dull T, Gross M, Goeddel D, Ullrich A . DNA sequence of two closely linked human leukocyte interferon genes. Science. 1981; 212(4499):1159-62. DOI: 10.1126/science.6165082. View

13.

Hoofnagle J, Mullen K, Jones D, Rustgi V, Di Bisceglie A, Peters M . Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315(25):1575-8. DOI: 10.1056/NEJM198612183152503. View

14.

Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D . Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354(7):709-18. DOI: 10.1056/NEJMoa053007. View

15.

de Weerd N, Vivian J, Nguyen T, Mangan N, Gould J, Braniff S . Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1. Nat Immunol. 2013; 14(9):901-7. DOI: 10.1038/ni.2667. View

16.

Thomas C, Moraga I, Levin D, Krutzik P, Podoplelova Y, Trejo A . Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; 146(4):621-32. PMC: 3166218. DOI: 10.1016/j.cell.2011.06.048. View

17.

Misasi J, Sullivan N . Camouflage and misdirection: the full-on assault of ebola virus disease. Cell. 2014; 159(3):477-86. PMC: 4243531. DOI: 10.1016/j.cell.2014.10.006. View

18.

Piehler J, Thomas C, Garcia K, Schreiber G . Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev. 2012; 250(1):317-34. PMC: 3986811. DOI: 10.1111/imr.12001. View

19.

Li Z, Strunk J, Lamken P, Piehler J, Walz T . The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling. J Mol Biol. 2008; 377(3):715-24. PMC: 2577817. DOI: 10.1016/j.jmb.2007.12.005. View

20.

Bidwell B, Slaney C, Withana N, Forster S, Cao Y, Loi S . Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012; 18(8):1224-31. DOI: 10.1038/nm.2830. View